UNSPSC 51383302: Aceclofenac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RPK779R03H, chemically known as 2-(o-(2,6-dichloranilino)phenylacetoxy)essigsaeure but generally known as aceclofenac, which bears US NIH Compound Identifier 71771. European Medicines Agency schedules Aceclofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05200MIG.

UNSPSC 51383302 Aceclofenac is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, though recent opportunities show a broader scope of pharmaceutical and over-the-counter (OTC) product sourcing rather than the specific anti-inflammatory drug the code nominally names. State and local governments use this code tier to procure generic multi-source pharmaceuticals, naloxone, OTC products, and related drug-supply contracts through health departments, cooperative purchasing alliances, and county health systems. Issuing bodies include state health and human services commissions, county health departments, and multistate cooperative purchasing organizations; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and Texas Health and Human Services Commission appear as active buyers in the recent record.

Recent activity spans Texas, Florida, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries and fixed-fee pricing with a two-year initial term and one-year renewal option. The Texas HHS Commission posted a Request for Information (RFI HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative outside traditional pharmacy benefit manager and wholesaler channels. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products, requiring products to be available by May 15, 2026 and contracts effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness, and vendors required to maintain relationships with at least two of three authorized wholesalers and carry $5 million commercial general liability coverage.